



**HAL**  
open science

## Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study

Jacques Bouget, Frédéric Balusson, Maxime Maignan, Laure Pavageau, Pierre-Marie Roy, Karine Lacut, Lucie-Marie Scailteux, Emmanuel Nowak, Emmanuel Oger

### ► To cite this version:

Jacques Bouget, Frédéric Balusson, Maxime Maignan, Laure Pavageau, Pierre-Marie Roy, et al.. Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study. *British Journal of Clinical Pharmacology*, 2020, 86 (12), pp.2519-2529. 10.1111/bcp.14362 . hal-02635140

**HAL Id: hal-02635140**

**<https://univ-rennes.hal.science/hal-02635140>**

Submitted on 9 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

SCAILTEUX Lucie-Marie (Orcid ID: 0000-0001-7047-9107)

Oger Emmanuel (Orcid ID: 0000-0001-9837-2977)

**Major bleeding risk associated with oral anticoagulant in real clinical practice.**

**A multicentre 3-year period population-based prospective cohort study**

Short running title: Major bleeding risk and oral anticoagulant

Jacques BOUGET<sup>1</sup>, Frédéric BALUSSON<sup>1</sup>, Maxime MAIGNAN<sup>2</sup>, Laure PAVAGEAU<sup>3</sup>, Pierre-Marie ROY<sup>4</sup>, Karine LACUT<sup>5</sup>, Lucie-Marie SCAILTEUX<sup>1</sup>, Emmanuel NOWAK<sup>5</sup> and Emmanuel OGER<sup>1</sup>

The authors confirm that the Principal Investigator for this paper is Jacques BOUGET and that he had direct clinical responsibility for patients.

<sup>1</sup>Univ Rennes, CHU Rennes, EA 7449 [Pharmacoepidemiology and Health Services Research]

REPERES, F 35043 Rennes, France, <sup>2</sup>Emergency Department, University Hospital, F 38043

Grenoble, France, <sup>3</sup>Emergency Department, University hospital, F 44093 Nantes, France,

<sup>4</sup>Emergency Department, University hospital, F 49033 Angers, France, <sup>5</sup>CIC 1412, Université

de Bretagne Loire, Université de Brest, INSERM, CHRU de Brest, F 29200 Brest

**Correspondence:** Emmanuel Oger, email: emmanuel.oger@univ-rennes1.fr, phone +33223234713, University of Rennes 1, EA 7449 [Pharmacoepidemiology and Health Services Research] REPERES, F 35043 Rennes

**Keywords:** oral anticoagulant, major bleeding, real-world data

**Registration:** ClinicalTrials.gov identifier: NCT02886533.

**Abstract** (245 words)

### **AIMS**

The objective was to compare major bleeding risk of DOACs (per type and dose) with VKAs, irrespective of indication, using real-world data.

### **METHODS**

A population-based prospective cohort study, using the French national health data system (SNIIRAM), identified 47,469 adults living within five well-defined geographical areas, who were new users of oral anticoagulants in the period 2013-2015: 20,205 VKA users, 19,579 rivaroxaban users, 4,225 dabigatran users and 3,460 apixaban users. From all emergency departments within these areas, clinical data for all adults referred for bleeding was collected and medically validated. The databases were linked for common key variables. The main outcome measure was major bleeding: intracranial haemorrhage, major gastrointestinal bleeding and other major bleeding events. Hazard ratios were derived from adjusted Cox proportional hazard models. We used propensity score weighting as a sensitivity analysis, with separate analyses according to indications (atrial fibrillation or venous thromboembolism).

## RESULTS

Compared to VKAs, high and low-dose DOACs were associated with a reduced risk of intracranial haemorrhage (adjusted hazard ratio 0.55, 95% confidence interval 0.37 to 0.82 and 0.54, 0.26 to 1.12 respectively), and a reduced risk of other major bleeding events (0.41, 0.29 to 0.58 and 0.41, 0.22 to 0.79 respectively), irrespective of duration and indication. Neither DOAC dose evidenced any significant difference from VKAs in terms of risk of major gastrointestinal bleeding.

## CONCLUSIONS

There is a clear benefit of using DOACs with regard to intracranial haemorrhage. The study provides new insight into major gastrointestinal and other major bleeding events.

### STATEMENT1: WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

- Meta-analyses of randomized trials have identified higher rates of gastrointestinal bleeding for DOACs compared to warfarin.
- All DOACs significantly reduce the risk of intracranial bleeding compared to adjusted-dose warfarin.
- Observational studies on real-world data, mostly based on reimbursement claims, have been inconsistent and generally imprecise.

### STATEMENT2: WHAT THIS STUDY ADDS

- This study included new users of oral anticoagulants, irrespective of indication, thus broadening the view on safety issues.
- The medical validation of all bleeding events supports the validity of the results.

- DOACs were associated with a decreased risk of other (non-gastrointestinal non-intracranial) major bleeding events among patients, irrespective of duration, dose and indication, compared to VKAs.

## Introduction

Anticoagulants have demonstrated significant benefits in preventing venous or arterial thrombotic events, especially for stroke, atrial fibrillation (AF), venous thromboembolism (VTE) and in presence of mechanical heart valves [1]. These drugs are commonly prescribed, and their long-term use has been on the increase, particularly among the elderly.

Bleeding is the most well-known and feared complication of anticoagulants. Numerous studies on drug-induced adverse events have reported anticoagulants as the first medication class involved in resort to emergency departments and hospitalization among adults [2], mostly for haemorrhage, and particularly intracranial haemorrhage (ICH), which results in substantial morbidity and mortality [3].

Direct oral anticoagulants (DOACs), including direct thrombin inhibitors and factor Xa inhibitors, are now available for the prevention of stroke and systemic embolism. Pivotal randomised clinical trials (RCTs) have reported a very considerable reduction in the relative risk of ICH, ranging from 23% for rivaroxaban [4] to almost 70% for dabigatran etexilate 110 mg twice daily [5]. Major gastrointestinal (GI) bleeding under DOACs has been either as frequently observed as with warfarin [5,6] or more frequently observed [4,5] than with warfarin.

Real-world data on bleeding risk is needed, particularly as the selection criteria applied to RCTs may have artificially improved the picture. Trial patients often have a lower risk of bleeding than do those in ordinary practice, because trials often exclude patients with the

highest risk. It is important to know whether the bleeding event rates observed in RCTs are reflected in routine clinical practice, and whether there are differences across the different DOACs for bleeding risk.

Several analyses using large reimbursement claims databases have yielded reassuring findings in line with those from RCTs: a lower rate of ICH with both doses of dabigatran [7-18], with rivaroxaban [16,18-20] and with apixaban [13,16,18,20], similar [7,8,10,11,14,17,18] or higher rates of GI bleeding associated with dabigatran [7,8,9,12,13,21] or rivaroxaban [18,22] compared to warfarin; and lower rates of GI bleeding associated with apixaban [13,18]. Data on dabigatran from the US is also reassuring, bearing in mind that the FDA has not authorised the 110 mg dose for AF patients [10,12,17,21,23-27].

Meta-analyses [28-31] of these observational studies on real-world data, mostly based on reimbursement claims, concluded to heterogeneity across studies. Assessing bleeding from reimbursement claims is liable to be influenced by variability in coding and misclassification, which could bias relative risk estimates. In addition, most studies focused on patients with non-valvular AF. Only three studies have provided data for a wider population [23,25,32]. We conducted a population-based cohort study within well-defined areas, including new users of oral anticoagulants, collecting data prospectively and medically validating all major bleeding events over a three-year period. Our main objective was to compare major bleeding risk per type and dose of DOACs with VKAs, whatever the indication.

## Methods

### *Study design and participants*

We conducted a prospective population-based cohort study using the French national health insurance database (SNIIRAM). We were provided access to a subset of all adult subjects (> 18 years) living within five well-defined areas, with at least one reimbursement for an oral anticoagulant (dabigatran, rivaroxaban, apixaban or VKA) in 2013-2015. In order to medically validate all bleeding events occurring in this cohort, we linked these individuals to an ad-hoc data collection from all emergency departments, either public or private, located in these five areas. The areas were defined using lists of postcodes around five large French cities (Angers, Brest, Grenoble, Nantes and Rennes, all with a university hospital, covering slightly more than 3 million inhabitants). This list comprises all municipalities in which inhabitants are referred in case of need to one of the participating emergency services . The study received regulatory approval (CNIL, DR-2013-488, with subsequent substantial changes DR-2016-489).

Firstly, the SNIIRAM anonymously and comprehensively links a healthcare reimbursement database (DCIR) to the French hospital discharge database (PMSI): the DCIR contains anonymous individual data on all reimbursements for health expenditure, including drugs; the database does not provide any direct information on the medical indication for each reimbursement; the PMSI provides hospital discharge diagnoses (ICD-10 code) as well as details of medical acts.

Secondly, an ad-hoc data collection from emergency departments gathered clinical data for all adult subjects referred for bleeding between January 1, 2013 and December 31, 2015, focusing on oral anticoagulants, the type of bleeding, and also collecting demographics (month and year of birth, gender) and date of hospital admission. To identify patients

referred for bleeding, the first step was a search based on carefully-chosen haemorrhage-related diagnostic codes or the implementation of specific emergency therapies (red blood transfusion, platelet transfusion, vitamin K, protamin sulfate, prothrombin complex concentrate and FEIBA). This search was applied to the electronic health records from emergency departments. A pilot study found good sensitivity for the computer search [33].

In each area, a referent expert medical doctor checked all records identified for oral anticoagulant exposure and severe bleeding criteria (see below for details).

Thirdly, the SNIIRAM sample and the ad-hoc data collection sample were linked using common key variables (date of birth (month, year), gender, date of hospital entry and discharge, type of oral anticoagulant, and care facility involved). Pairs were defined from emergency department stays identified in the SNIIRAM subset, matched on the key variables to a bleeding event in the ad-hoc data collection (see reference [34] for matching details).

### ***Outcomes***

We anticipated that the estimates for associations between anticoagulant and major bleeding could be heterogeneous across the three types of major bleeding, and we therefore defined three classes for the primary outcome: ICH, GI bleeding and other major bleeding events. Major bleeding was defined from at least one of the following criteria: unstable haemodynamics (systolic arterial pressure < 90 mmHg or mean arterial pressure < 65 mm Hg) or haemorrhagic shock, uncontrollable bleeding, need for transfusion or haemostatic procedure (embolization, endoscopic procedure, surgery). The location or the symptoms then defined the type: ICH for intracranial haemorrhage, acute GI bleeding, and other major bleeding in life-threatening locations - intraspinal, intraocular, retroperitoneal,



pericardial, thoracic, intra-articular, or intramuscular haematoma with compartment syndrome. We also considered epistaxis with at least two procedures of nasal packing, and hematuria when bleeding lasted more than 12 hours despite bladder washing as "other" major bleeding events. There was a slight alteration with respect to the International Society on Thrombosis and Haemostasis (ISTH) classification of major bleeding events [35] because in our dataset no information was available on haemoglobin levels.

The secondary outcome was all-cause mortality.

***Main exposure: oral anticoagulant***

Only "new users", defined as having had no oral anti-coagulant exposure in 2012, were analysed.

The indication for anticoagulant prescription was derived from the main discharge diagnosis and/or medical acts performed in the 30 days before the first observed issue of anticoagulant (Table S1 for code definitions). "Medical acts" include imagery procedures such as Doppler ultrasonography (of the lower limb for a suspicion of deep vein thrombosis, echocardiography), CT scan, MRI; and therapeutic procedures (thrombectomy, fibrinolysis, thrombo-aspiration, transcatheter cardio-version, plaster cast, osteosynthesis, orthopaedic surgery, valve surgery, vascular by-pass, angioplasty, coronary surgery).

For patients who were not hospitalised and had no "medical act" within a month of the start of OACs, the indication was not determined, and classified as 'unknown'. For the at-risk cohort identified through the SNIIRAM database, we classified person-month exposure to dabigatran, rivaroxaban, apixaban or VKAs on the basis of their issue dates. Exposure groups and index dates were defined at first dispensation. We differentiated high-dose (dabigatran 300 mg or rivaroxaban 15 or 20 mg or apixaban 10 mg per day) and low-dose (dabigatran

220 mg or rivaroxaban 10 mg or apixaban 5 mg per day). For DOACs, they are prescribed at fixed doses and the quantity dispensed by pharmacists is limited by law to 30 days, so the number of days of supply was established as [last issue date minus first issue date] plus 30 days. For VKAs, computing supply was not straightforward as we lacked information on dosing instructions. The number of days of supply was established as [last issue date minus first issue date] plus 60 days; we checked that there was at least one INR measure within the previous two months.

Patients were censored in case of discontinuation of oral anticoagulants (using the end date of supply as previously described) or switch (from VKAs to DOACs or vice versa), or date of dose change for DOACs (from high-dose to low-dose or vice-versa), or death, or major bleeding event (as previously defined), or moving outside the area, or end of follow-up, whichever occurred first.

The main exposure was further subdivided according to whether the anticoagulant drug was prescribed alone or in combination with an antiplatelet drug (aspirin, clopidogrel, ticagrelor, or prasugrel) and according to the duration of use (under 6 months, 6 to 12 months or over one year).

### ***Statistical analysis***

Patient characteristics and descriptive incidence rates were explored first. Co-morbidities (Table S1 for code definitions) and co-medication (listed in Table 1) were retrieved from SNIIRAM. We calculated a modified HAS-B(L)ED score (adapted from Pister et al. [36]) as a measure of bleeding risk and a co-morbidity score (Charlson's index adapted by Bannay et al. [37], see Tables S2 and S3 for definitions of scores). Crude incidence rates (IR) were calculated for the first bleeding episode per 10,000 person-months according to the type of

bleeding, the type of oral anticoagulant (VKAs, DOAC high-dose or DOAC low-dose), and the duration of use (under 6 months, 6 to 12 months or over one year) and the HAS-B(L)ED score level.

Cox proportional hazard regression analyses were conducted for each type of bleeding event to determine hazard ratios for DOACs (high-dose or low-dose) versus VKAs, both unadjusted and adjusted on known patient characteristics: gender, modified HAS-B(L)ED score, and co-morbidities using the modified Charlson index. For each particular type of bleeding event, censoring occurred when death or any other type of bleeding event occurred, whichever first.

For each outcome we tested interactions between exposure and gender, modified HAS-B(L)ED score (<2, 2 and  $\geq 3$ ), and the modified Charlson index (four classes). We also tested interaction with time. Subgroup analyses were performed for some components of the HAS-BLED score: firstly, a concomitant antiplatelet regimen defined as any antiplatelet agents dispensed at least once concomitantly with oral anticoagulant after the index date, and secondly age (under or over 65 years).

As a secondary analysis, Cox proportional hazard regression models were run to estimate overall survival for DOACs (high-dose or low-dose) versus VKAs.

We conducted four sensitivity analyses to assess the robustness of our findings. First, we restricted the study population to patients without a presumed orthopaedic indication and ran the same Cox model used in the main analysis. Second, we performed separate analyses for the two main indications, AF or stroke, and acute venous thromboembolism. We regenerated the probability of treatment, DOACs (high-dose or low dose) versus VKAs in the AF or stroke population, and DOACs (high-dose) versus VKAs in the acute venous thromboembolism population using logistic regression models (a multinomial regression in

the AF or stroke population) using 22 pre-specified variables (listed in Tables S4 and S5 along with standardized differences). We then used the stabilized inverse probability of treatment weighting (SIPTW) based on the propensity score [38] as weights in Cox proportional hazard regression models. The weights were truncated by resetting the value of weights greater (or lower) than the 99th (1st) percentile to the value of the 99th (1st) percentile [39].

Covariate balance between the weighted cohorts was assessed using standardized mean differences. To estimate the impact of absolute risks, we calculated the numbers needed to harm using weighted hazard ratios [40]. Third, adjusted Cox proportional hazard regression models were run to compare different DOACs, using apixaban as a reference. Fourth, we identified any hospitalisation that occurred outside the pre-specified area, with ICD-10 codes as primary discharge diagnoses that could be related to major bleeding, using a published list: [41] indeed, some subjects can experience bleeding while on holiday or travelling (i.e. only temporarily outside the area), and therefore their bleeding event cannot be medically validated from chart review. Cox proportional hazard regression analyses were run using a modified dataset including these events. All statistical tests were two-tailed and P-values <0.05 were considered significant. Statistical analyses were performed using SAS software 9.4 (SAS Institute, Cary, N.C., USA). Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY

## **Results**

### ***Cohort characteristics***

A cohort generation flowchart is presented in Fig 1: 47,469 patients who had started anticoagulants between 2013 and 2015 (new users) were eligible for inclusion. Baseline characteristics in relation to the type of oral anticoagulant first prescribed are presented in

Table 1. The mean age was 70 years (median, 73 years, Q1-Q3, 62-82) and 51% were males.

In all, 52% were diagnosed with AF, leaving 48% of the patients prescribed anticoagulants for other indications: mostly a diagnosis of venous thromboembolism (VTE) (22%) or VTE prevention following lower limb orthopaedic surgery (13%).

Patients treated with rivaroxaban or dabigatran at high doses were younger, and more likely to be male. Patients treated with any of the DOACs whatever the dose had lower co-morbidity (modified Charlson index) and bleeding risk (modified HAS-B(L)ED) than patients treated with VKAs.

The median follow-up time was different between VKA, 234 days (25th, 75th percentile; 116, 510), high-dose, DOAC 163 days (67, 412), and low-dose DOAC, 60 days (60, 119).

The moment of censoring and the numbers and reasons involved are described in Figure S1 and Table S6.

The end of follow-up and treatment discontinuation were the most common reasons for censoring. End of follow-up was the first reason among Apixaban users (74% for high dose and 62% for low dose), which could be explained by the fact it was the last to join the market. Discontinuation ranked ahead of end of follow-up for low-dose Dabigatran and low-dose Rivaroxaban; this is intuitive, as low doses are associated with short-term treatment. Differences in follow-up or treatment discontinuation timing across anticoagulant classes could bias estimates if there was an interaction with time. We checked for an interaction of this nature and did not detect any significant interaction.

We observed that switching and dose change (for DOACs) were uncommon except for high-dose Dabigatran .

Lower limb orthopaedic surgery was the presumed indication observed for 5829 (60%) out of 9605 patients with low-dose DOAC. In this context, the duration of treatment is short (2 weeks for knee replacement and 5 weeks for hip replacement).

### ***Incidence rates***

A total of 573 (1.2%) patients experienced a first major bleeding episode. The fatality rate was  $56/573 = 9.77\%$ . Table S7 shows the number of bleeding events according to bleeding site and indication (panel A), and anticoagulant drug (panel B). Nearly all major bleeding events (98%) occurred among patients for whom an anticoagulant was prescribed for AF or VTE.

The crude incidence rates for all major bleeding were higher during the first 6 months of therapy than during the '6-12 months' period, overall (S2 Figure). There was a statistically significant linear association between HAS-B(L)ED and all major bleeding.

Among VKA users, the rates were higher for all bleeding sites, with higher HAS-B(L)ED scores (Table S8). Incidence rates for ICH and other major bleeding events were lower among DOAC users than VKA users irrespective of the DOAC dose (high or low).

We also observed 2196 deaths. The incidence rate per 100 person-years (95%CL) was 9.05 (8.63 to 9.49) for VKA, 2.25 (2.01 to 2.51) for high-dose DOAC, and 4.28 (3.71 to 4.94) for low-dose DOAC.

### ***Bleeding risk and anticoagulant exposure***

Forest plots showing adjusted HRs for each first bleeding episode and all-cause mortality for DOACs compared to VKAs are presented in Fig 2. There were no interactions for any bleeding outcome between anticoagulant exposure and gender, modified HAS-B(L)ED score,

or modified Charlson's index. The tests for interaction with time were all non-significant (p value > .15). Proportional hazard assumptions held true. All results were therefore derived from Cox multivariate proportional models including gender, modified HAS-B(L)ED score, and modified Charlson's index. Compared to VKAs, DOACs, either high or low-dose, were associated with a reduced risk of ICH and other major bleeding events, as well as with all-cause mortality. We observed consistent results across the different types of other major bleeding events (Figure S3). There was no obvious heterogeneity across the different types of DOACs in relation to any major bleeding outcome, or all-cause mortality (Figure S4). There was no statistically significant association between DOACs (whether low or high-dose) and major GI bleeding compared to VKAs (Figure 2 and S5). There were no relevant interactions for any bleeding outcome or for all-cause mortality between anticoagulant exposure and concomitant antiplatelet drug use or age (elderly people > 65 years, HASB(L)ED score level) (data not shown).

### ***Sensitivity analyses***

The results of the sensitivity analyses are summarized in Figures 2, 3 and S6. Restricting the study population to patients without presumed orthopaedic indications led to estimates close to the null, but still statistically significant for other major bleeding and all-cause mortality; very few events were lost (3 GI bleedings and 9 deaths) but person-time at risk decreased by 30% (Figure 2). Analyses were then conducted in sub-cohorts of new anticoagulant users with AF (n = 24,505) or VTE (n = 10,380). Using the SIPTW, the weighted cohorts were well balanced across all covariates (Tables S4 and S5).

Forest plots showing the weighted HRs for each bleeding event and all-cause mortality for DOACs compared to VKAs, are provided in Fig 3. Among patients with AF, DOACs were

associated with a lower risk of other major bleeding events, and better overall survival than VKAs. Neither dose showed significant differences from VKAs in terms of ICH risk or GI bleeding risk. The same pattern was observed among patients with VTE.

Forest plots showing adjusted HRs for all-cause mortality for dabigatran, rivaroxaban or VKAs, using apixaban as a reference, are provided in Figure S6. Among patients with AF, high-dose apixaban was associated with better overall survival than VKAs and rivaroxaban. A re-analysis including 93 major bleeding events occurring outside the study region did not change the hazard ratios (data not shown).

### ***Numbers-needed-to-harm***

Figure S7 shows the numbers-needed-to-harm to assess the risk of DOACs in comparison with VKAs. Overall, the number-needed-to-harm (to observe one extra ICH or any other major non-GI bleeding event) remained fairly high.

### **Discussion**

This population-based cohort study was based not only on an administrative healthcare database, but also on a prospective clinical data collection with medical validation of all bleeding events. It showed a decreased risk of ICH, other major non-GI bleeding events, and all-cause mortality associated with the use of DOACs, whether low- or high-dose, irrespective of duration and indication, compared to VKAs. Neither DOAC dose differed significantly from VKAs in terms of GI bleeding risk. Among patients with AF, high-dose apixaban was associated with better overall survival than VKAs or rivaroxaban. Our findings for new anticoagulant users generally, whatever the indication, provide more generalisable evidence than findings from subsets of patients with only AF or VTE.



**Strengths.** Our large comprehensive study is unique by its ability to directly compare different DOACs, including the different doses, encompassing all indications, in the exploration of an important and common safety outcome. This minimizes a bias that affects the external validity of studies focusing on hospital data only, whereby patients diagnosed and managed in primary care are not included. Indeed, roughly the same numbers of patients without AF are also prescribed anticoagulants (note the 48% in our study). We thus enhanced representativeness. We hypothesised that bleeding risk related to oral anticoagulants was mostly related to patient characteristics, not to the indication for anticoagulant use.

The other strength of our study is that it retrieves and links data from a prospective multi-centre clinical study and data from a public healthcare system database that covers all residents within the defined area. As a result, the overall dataset gave us a complete picture of all hospitalizations and prescriptions dispensed, as well as the medical validation of bleeding events. On the one hand, this complete data coverage within the defined area eliminates a potential selection and recall bias, which is a problem in hospital-based observational studies; on the other hand, the clinical data enhances the validity of outcome measurements, minimising classification bias, which is a problem in administrative databases. There is indeed a risk of misclassification related to coding errors at the time of hospital admissions; this may not be very likely for serious conditions like bleeding. However, the absence of validation could lead to overestimating incidence rates for major GI bleeding or urogenital bleeding [42].

We adopted a new-user design capturing all events after the start of treatment. We ran a Cox proportional hazard model as the main analysis, adjusting for all available confounding

factors, and we also undertook a sensitivity analysis using stabilized inverse probability of treatment weighting using a propensity score, which showed similar results.

**Limitations.** Exposure in our study was based on reimbursement claims data. We studied drug exposure on the basis of pharmacy dispensations but had no information on patients' actual intake. The lack of information on patient adherence could have led to incorrect estimations of exposure, but the clinical validation of major bleeding made it possible to check that patients were still receiving anticoagulants at the time of bleeding.

Bleeding events could be more likely to be detected among patients prescribed VKAs than among those taking DOACs, introducing a surveillance bias, because of the regular monitoring required for VKA users. As major bleeding requires hospital referral, it is less likely to be missed among patients taking DOACs. This limitation does not apply to deaths.

Although we extensively adjusted for baseline differences, which should have helped to reduce the possible indication bias, it is unlikely that we captured the full extent of different prescribing behaviours, and some unmeasured, residual confounding factors could still be present. Our study lacked certain patient characteristics (such as smoking and weight - but we think they are not really confounders), or time-within-therapeutic-range for patients receiving VKAs.

Covering all indications and also including patients who received low-dose DOAC for brief thromboprophylaxis after orthopaedic surgery may have impacted the overall estimate.

Sensitivity analyses, restricting the study population either to patients without a presumed orthopaedic indication, or to patients with AF, showed consistent estimates, closer to the null than that for the entire population, but still significant for other major bleeding.

**Discussion of main results in relation to other studies.** In the comparison of our findings with pivotal outcome trials and observational studies, caution is required, as there are differences in the study populations, definitions of bleeding and healthcare systems, as well as other factors that are difficult to take into account. To facilitate comparison with other studies, we show analyses separately for patients with AF and VTE, and for high or low-dose DOAC.

Incidence rates for bleeding events for patients taking warfarin or VKAs highlight the way in which previous observational studies differ from ours, as incidence rates are linked to a number of risk factors. In other word, by comparing incidence rates among patients taking warfarin or VKAs, we thought we could compare background characteristics of the populations under study. Our findings were in line with Danish studies [43,44] as well as with a study in the UK [32] for GI bleeding rates and ICH rates, but our rates were much lower than those reported in studies using US insurance data [12,23,25].

***Intracranial haemorrhage.*** A recent meta-analysis [30] of observational studies reported a large effect of all three DOACs studied on ICH, with relative reductions in incidence of 36% for rivaroxaban, 55% for apixaban, and 58% for dabigatran. There was significant heterogeneity for rivaroxaban. The studies included focused on patients with AF. However, a more recent study [32], not included in the meta-analysis, showed that the use of rivaroxaban was associated with a lower risk of ICH among patients without AF but not among patients with AF.

***Gastrointestinal bleeding.*** In landmark trials [4–6], dabigatran and rivaroxaban were both associated with a higher rate of GI bleeding than warfarin, whereas apixaban had a lower rate. Since then, numerous post hoc analyses and meta-analyses of this data have concluded that DOACs were likely to involve a higher risk of GI bleeding compared to

warfarin, which was related to the use of higher doses, particularly for dabigatran [45–49].

There was no standard definition of GI bleeding in the RCTs, limiting the interpretation of the data, collected as adverse events and coded as such. Moreover, the use of warfarin in the clinical trial setting is likely to be higher than its use in daily practice. Finally, patients enrolled in clinical trials are often not representative of real-world practice. Reports from observational studies using various large administrative datasets have reported contradictory findings [7,12,14,23,25,26,50], and all have had substantial limitations.

Mainly, their data is conditional on the accuracy of administrative coding for diagnoses, and the primary outcome of GI bleeding was not reviewed. One study suggested that the risk of GI bleeding, validated by a manual chart review, was lower with the use of DOACs than with warfarin, irrespective of the indication [51]. More recently, a study in primary care setting reported that apixaban was associated with a decreased risk of GI bleeding, irrespective of indication [32]. Our study reported no significant difference for either high or low-dose DOACs compared to VKAs. It is worth noting that not all patients admitted for GI bleeding were categorised as having an outcome because our criteria for major bleeding were more stringent, based on clinical judgement and not solely relying on hospital referral.

***Other major bleeding events.*** Few studies have reported on major bleeding events other than ICH and GI bleeding. In a multicenter prospective study, Becattini et al. reported heterogeneous results with significantly more frequent hematuria and upper airway bleeding events and less frequent retroperitoneal and soft/tissue hematomas with DOACs compared to VKAs [52]. A large real-world evaluation in the USA based on elderly Medicare patients with nonvalvular AF reported consistent results across all major bleeding events when comparing apixaban to warfarin, but it also reported some heterogeneity when comparing dabigatran (mostly high-dose) or rivaroxaban to warfarin [53]. A nationwide

Norwegian registry study showed a statistically significant reduction in "other" major bleeding events when comparing dabigatran or apixaban (mostly high-dose for both) to warfarin [13]. A cohort of patients with nonvalvular AF from a large US commercial database combined with Medicare initiating dabigatran or warfarin treatment showed a statistically significant reduction for other major bleeding events with dabigatran [26]. Definition was based on an algorithm using administrative inpatient claims with either a primary or secondary diagnosis [13,26,53] and these studies reported higher incidence rates than our study. However, our main analysis, combining all DOACs, showed a similar pattern for "other" major bleeding events to that for ICH. In addition, we observed consistent results across the different types of bleeding.

***Major bleeding and all-cause mortality.***

A meta-analysis of DOAC trials found a 10% reduction in all-cause mortality with high-dose DOACs compared to warfarin [49]. However, mortality was not significantly different between rivaroxaban and warfarin [4], whereas the mortality reduction was significant for apixaban (11% reduction)[6] and of borderline significance for high-dose dabigatran [5]. A meta-analysis of observational studies identified 6 studies involving 319,486 patients that compared dabigatran to VKAs with regard to survival and concluded to a significant benefit with dabigatran, but with substantial heterogeneity across studies [30]. Only one study involving 41,785 patients reported better survival rates with apixaban than with VKAs [43]. There was no statistical difference between rivaroxaban and VKAs for death in two studies that included 51,795 patients [19,30]. There was again significant heterogeneity. Our analysis is in line with these observations, showing a differential effect of DOACs, with better overall survival with high-dose apixaban compared to rivaroxaban or warfarin,

whereas there was no substantial difference between high-dose dabigatran and apixaban among patients with AF.

To conclude, our study in real-world practice confirms a clear benefit for DOACs with regard to ICH. It provides new insight into major GI and other major bleeding events, by integrating a medical validation of all bleeding events. While there is reassurance concerning the safety of DOACs for other major non-GI bleeding events, neither dose of DOACs differed significantly from VKAs for major GI bleeding. It is worth noting that incidence rates for major bleeding remained fairly low with DOACs and the numbers needed to observe one ICH or one other major bleeding event remained fairly large. Lastly, there was a substantial benefit of DOACs in relation to all-cause mortality.

### **Acknowledgement**

This study was supported by the National Clinical Research Hospital Program of the French Ministry of Health (PHRC-12-009-0243). The funding source had no role in study design, data collection, analysis, or interpretation.

### **Contributors**

JB, EO, EN participated in the analysis and interpretation of the data and the drafting of the manuscript. JB and EO participated in the study concept and design. JB, EO, EN, FB, MM, LP, PMR, KL and LMS participated in the critical revision of the report. EN, FB participated in the statistical analyses.

### **Declaration of interests**

We have no competing interests to declare.

### **Data access and cleaning methods**

The authors (JB, FB, EN and EO) had full access to all of the data (extracted from SNIIRAM and clinical database) that was used to generate the study population. The database extracted was stored locally in a dedicated and secure data centre: extraction was performed by CNAMTS; csv data files were imported into the MySQL database with a physical data model consistent with the original SNIIRAM database design; investigators had no direct access to SNIIRAM. Metrics and visual tools were used to check data completeness and fit to expected data extraction: the metrics included the number of patients extracted (compared to the expected number), and the stability of reimbursement frequencies over time in order to validate data completeness at a population level.

#### **Data sharing**

The statistical code is available from the corresponding author. Under French law and regulations, patient-level data from SNIIRAM cannot be made available.

## References

1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141:e44S–e88S.
2. Budnitz DS, Lovergrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med* 2011;365:2002–12.
3. Witt DM, Delate T, Hylek EM, et al. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. *Thromb Res* 2013;132:770–5.
4. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non valvular atrial fibrillation. *N Engl J Med*. 2011;365:883–91.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139–51.
6. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981–92
7. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real world” patients with atrial fibrillation: A prospective nationwide cohort. *J Am Coll Cardiol*. 2013;61:2264–73.
8. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GYH. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. *Am J Med* 2014;127:650–6.
9. Avgil-Tsadok M, Jackevicius CA, Essebag V, et al. Dabigatran use in elderly patients with atrial fibrillation. *Thromb Haemost* 2016;115:152-160.
10. Bengtson LG, Lutsey PL, Chen LY, MacLehose RF, Alonso A. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. *J Cardiol* 2017; 69:868–76.
11. Chan YH, Yen KC, See LC, et al. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. *Stroke* 2016;47:441–9.
12. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. *Circulation* 2015;131:157–64.
13. Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. *Eur Heart J Cardiovasc Pharmacother* 2017;3:28-36.



14. Nishtala PS, Gnjidic D, Jamieson HA, Hanger HC, Kaluarachchi C, Hilmer SN. 'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. *Int J Cardiol* 2016;203:746–52.
15. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. *Thromb Haemost* 2015;114:1277–89.
16. Staerk L, Fosbol EL, Lip GYH, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin k antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: A nationwide cohort study. *Eur Heart J* 2017;38:907–15.
17. Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. *Thromb Haemost* 2015;114:1290–8.
18. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. *J Am Heart Assoc* 2016;5:e003725.
19. Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in asians with nonvalvular atrial fibrillation. *J Am Coll Cardiol* 2016;68:1389-1401.
20. Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the united states: The REVISIT-US study. *Curr Med Res Opin* 2016 Dec;32(12):2047–53.
21. Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E, Cram P. Bleeding rates in veterans affairs patients with atrial fibrillation who switch from warfarin to dabigatran. *Am J Med* 2014;127:1179–85.
22. Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. *Curr Med Res Opin* 2014;30:1317–25.
23. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. *BMJ* 2015;350:h1857.
24. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. *JAMA Intern Med* 2015;175:18-24.

25. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. *BMJ* 2015;350:h1585.
26. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world us patients with non-valvular atrial fibrillation: A retrospective cohort study. *J Am Heart Assoc* 2015;4: e001798.
27. Lip GYH, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: A "real-world" observational study in the united states. *Int J Clin Pract* 2016;70:752–63.
28. Carmo J, Costa FM, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. *Thromb Haemost* 2016; 116:754-763.
29. Weeda ER, White CM, Peacock WF, Coleman CI. Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis. *Curr Med Res Opin* 2016;32:1117–20.
30. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of nonvitamin-k antagonist oral anticoagulants versus vitamin-k antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. *Stroke* 2017;48:2494-2503.
31. Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. *Stroke* 2018;49:98–106.
32. Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. *BMJ* 2018;362:k2505.
33. Oger E, Botrel MA, Juchault C, Bouget J. Sensitivity and specificity of an algorithm based on medico-administrative data to identify hospitalized patients with major bleeding presenting to an emergency department. *BMC Med Res Methodol*. 2019 Oct 18;19(1):194.
34. Bouget J, Balusson F, Scailteux LM, et al. Major bleeding with antithrombotic agents: a 2012-2015 study using the French nationwide Health Insurance Database (SNIIRAM) linked to emergency departments records within five areas. Rationale and design of SACHA study. *Fundam Clin Pharmacol* 2019;33(4):443-462.
35. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S for the Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *J Thromb Haemost* 2015;13:2119–26.

36. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GYH. A novel user friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;138:1093–1100.
37. Bannay A, Chaignot C, Blotière PO, et al. The best use of the charlson comorbidity index with electronic health care database to predict mortality. *Med Care* 2016;54:188–94.
38. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behav Res.* 2011;46:399-424.
39. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. *Am J Epidemiol* 2008;168:656–64.
40. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. *BMJ* 1999;319:1492-5.
41. Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists : a French nationwide propensity-matched cohort study. *Circulation* 2015;132:1252-1260.
42. Ruigómez A, Brobert G, Suzart-Woischnik K, García-Rodríguez LA. Ascertainment and validation of major bleeding events in a primary care database. *Pharmacoepidemiol Drug Saf* 2018 Jun 27.
43. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GYH. Comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. *BMJ* 2016;353:i3189.
44. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GYH, Larsen TB. Effectiveness and safety of low-dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. *BMJ* 2017;356:j510.
45. He Y, Wong IC, Li X, Anand S, et al. The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. *Br J Clin Pharmacol* 2016;82:285-300.
46. Caldeira D, Barra M, Ferreira A, et al. Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. *Aliment Pharmacol Ther* 2015;42:1239–49.
47. Loffredo L , Perri L , Violi F. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: a meta-analysis of interventional trials . *Dig Liver Di.* 2015;47:429–31.


48. Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non-vitamin k antagonist oral anticoagulants: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2017;15:1674–83.
49. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;383:955–62.
50. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. *JAMA Intern Med* 2016; 176:1662–71.
51. Cangemi DJ, Krill T, Weideman R, Cipher DJ, Spechler SJ, Feagins LA. A comparison of the rate of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants or warfarin. *Am J Gastroenterol* 2017;112:734–9.
52. Becattini C, Franco L, Beyer-Westendorf J, et al. Major bleeding with vitamin K antagonists or direct anticoagulants in real-life. *Int J Cardiol* 2017;227:261–6.
53. Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. *Curr Med Res Opin* 2017;33:1595-1604.

**Table 1** Characteristics of subjects by drug exposure

Characteristics	VKA N = 20 205	Dabigatran Low N = 2 944	Dabigatran High N = 1 281	Rivaroxaban Low N = 5 246	Rivaroxaban High N = 14 333	Apixaban Low N = 1 415	Apixaban High N = 2 045
Age, median (Q1-Q3)	77 (64-85)	76 (65-83)	67 (60-74)	68 (60-76)	69 (58-79)	82 (74-86)	72 (64-78)
> 65 years	14616 (72.3)	2200 (74.7)	744 (58.1)	3028 (57.7)	8542 (59.6)	1224 (86.5)	1473 (72.0)
Gender, female	10354 (51.2)	1533 (52.1)	445 (34.7)	2892 (55.1)	6451 (45.0)	825 (58.3)	751 (36.7)
Presumed indication <sup>a</sup>							
AF or peripheral embolism or stroke	11535 (57.1)	1275 (43.3)	946 (73.8)	242 (4.6)	7774 (54.2)	913 (64.5)	1820 (89.0)
VTE	5662 (28.0)	-	53 (4.1)	-	4598 (32.1)	-	67 (3.3)
Lower limb orthopaedic surgery	218 (1.1)	1138 (38.7)	-	4371 (83.3)	-	320 (22.6)	-
Valvular heart disease	406 (2.0)	-	5 (0.4)	-	28 (0.2)	1 (0.1)	6 (0.3)
Other or unknown	2384 (11.8)	531 (18.0)	277 (21.6)	633 (12.1)	1933 (13.5)	181 (12.8)	152 (7.4)
Comorbidities <sup>b</sup>							
Diabetes mellitus	3204 (15.9)	327 (11.1)	178 (13.9)	503 (9.6)	1564 (10.9)	194 (13.7)	333 (16.3)
Coronary heart disease	2451 (12.1)	131 (4.4)	65 (5.1)	104 (2.0)	595 (4.2)	123 (8.7)	126 (6.2)
Hematologic or immune disease	1581 (7.8)	69 (2.3)	14 (1.1)	147 (2.8)	301 (2.1)	55 (3.9)	40 (2.0)
Medication use							
Lipid-lowering drug (last year)	8471 (41.9)	1135 (38.6)	466 (36.4)	1607 (30.6)	4718 (32.9)	567 (40.1)	949 (46.4)
Antiulcer agent (last year)	10626 (52.6)	1434 (48.7)	496 (38.7)	3291 (62.7)	6045 (42.2)	707 (50.0)	856 (41.9)
Antiplatelet agents (recent use)	6320 (31.3)	847 (28.8)	365 (28.5)	723 (13.8)	3579 (25.0)	536 (37.9)	729 (35.6)
NSAID (last year)	5000 (24.7)	1117 (37.9)	455 (35.5)	3341 (63.7)	4841 (33.8)	395 (27.9)	552 (27.0)
Modified HAS-B(L)ED score <sup>c</sup>							
0 – 1	8151 (40.3)	1399 (47.5)	751 (58.6)	2956 (56.3)	8614 (60.1)	547 (38.7)	1037 (50.7)
2	6661 (33.0)	1068 (36.3)	392 (30.6)	1560 (29.7)	4109 (28.7)	585 (41.3)	750 (36.7)
≥ 3	5393 (26.7)	477 (16.2)	138 (10.8)	730 (13.9)	1610 (11.2)	283 (20.0)	258 (12.6)

Concomitant medications <sup>d</sup>							
Antiplatelet agents	5218 (25.8)	503 (17.1)	194 (15.1)	719 (13.7)	1848 (12.9)	241 (17.0)	265 (13.0)
NSAID	1549 (7.7)	394 (13.4)	187 (14.6)	1736 (33.1)	1683 (11.7)	132 (9.3)	143 (7.0)
Modified Charlson comorbidity index <sup>e</sup>							
0	10060 (49.8)	2105 (71.5)	937 (73.1)	4410 (84.1)	10629 (74.2)	870 (61.5)	1379 (67.4)
1-2	6244 (30.9)	617 (21.0)	275 (21.5)	721 (13.7)	2867 (20.0)	392 (27.7)	512 (25.0)
3-4	2705 (13.4)	182 (6.2)	63 (4.9)	78 (1.5)	593 (4.1)	121 (8.6)	118 (5.8)
≥ 5	1196 (5.9)	40 (1.4)	6 (0.5)	37 (0.7)	244 (1.7)	32 (2.3)	36 (1.8)

Values are numbers (percentages) unless stated otherwise; high: dabigatran 300 mg or rivaroxaban 15 or 20 mg or apixaban 10 mg per day; low: dabigatran 220 mg or rivaroxaban 10 mg or apixaban 5 mg per day; <sup>a</sup> based on hospital discharge main diagnosis (according to ICD-10 or medical act classification in the month before the index date); <sup>b</sup> based on hospital discharge diagnosis (according to ICD-10 or co-medications (ATC system) in the previous year, see table S1 for details); <sup>c</sup> The HAS-BLED score assigns points for the presence of hypertension, abnormal renal or liver function, stroke, bleeding history, age 65 years or older, and antiplatelet drug or alcohol use. Labile INR was excluded from our scoring; see table S2 for details; <sup>d</sup> at least one delivery concomitant with any anticoagulant; <sup>e</sup> as defined by Bannay et al, see table S3 for details; NSAID denotes non-steroidal anti-inflammatory drug; recent use was defined by at least 2 deliveries in the 3 months before index date



**Figure 1. Study population**

High denotes full dose (dabigatran 300 mg or rivaroxaban 15 or 20 mg or apixaban 10 mg per day) and low, reduced dose (dabigatran 220 mg or rivaroxaban 10 mg or apixaban 5 mg per day) ; VKA denotes Vitamin K antagonist and DOAC direct oral anticoagulants.




Fig 2. Association estimates between each major bleeding event, all-cause mortality, and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)

Accepted






Fig 3. Association between each major bleeding event, all-cause mortality, and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA) for venous thromboembolism or stroke prevention with atrial fibrillation

Accepted

## Appendices

Table S1. Definition of presumed indication of oral anticoagulant, and co-morbidities.

Table S2. Items included in the modified HAS-BLED score

Table S3. Modified Charlson Score

Table S4. Baseline characteristics in unweighted and weighted cohorts of new users of DOAC or VKA for atrial fibrillation

Table S5. Baseline characteristics in unweighted and weighted cohorts of new users of DOAC high-dose or VKA for venous thromboembolism

Table S6. Timing of censoring according to reason and anticoagulant

Table S7 Panel A. Total number of major bleeding events according to indication

Table S7 Panel B. Total number of major bleeding events according to anticoagulant

Table S8. Crude incidence rates of bleeding events by anticoagulant exposure, dose and HAS-B(L)ED score level

Figure S1. Figure Reason of censoring (expressed as percentage) across drug classes.

Figure S2. Crude incidence rates of bleeding according to HAS-(B)LED strata and time period

Figure S3. Association estimates between different location of other major bleeding event, and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)

Figure S4. Association estimates between each major bleeding event, all-cause mortality, and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)

Figure S5. Association estimates between major gastrointestinal bleeding and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)

Figure S6. Association between all-cause mortality and dabigatran, rivaroxaban or vitamin K antagonist (VKA) compared to apixaban for stroke prevention with atrial fibrillation or acute venous thromboembolism (VTE)

Figure S7. Number needed to harm compared with vitamin K antagonist (VKA) considering intracranial and other major non gastrointestinal bleeding

Manuscript word count: 4754

## Supporting Information

<p>List of Supplementary Tables and Figures</p>	<p>Table S1. Definition of presumed indication of oral anticoagulant, and co-morbidities.</p> <p>Table S2. Items included in the modified HAS-BLED score</p> <p>Table S3. Modified Charlson Score</p> <p>Table S4. Baseline characteristics in unweighted and weighted cohorts of new users of DOAC or VKA for atrial fibrillation</p> <p>Table S5. Baseline characteristics in unweighted and weighted cohorts of new users of DOAC high-dose or VKA for venous thromboembolism</p> <p>Table S6. Timing of censoring according to reason and anticoagulant</p> <p>Table S7 Panel A. Total number of major bleeding events according to indication</p> <p>Table S7 Panel B. Total number of major bleeding events according to anticoagulant</p> <p>Table S8. Crude incidence rates of bleeding events by anticoagulant exposure, dose and HAS-B(L)ED score level</p> <p>Figure S1. Figure Reason of censoring (expressed as percentage) across drug classes.</p> <p>Figure S2. Crude incidence rates of bleeding according to HAS-(B)LED strata and time period</p> <p>Figure S3. Association estimates between different location of other major bleeding event, and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)</p> <p>Figure S4. Association estimates between each major bleeding event, all-cause mortality, and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)</p> <p>Figure S5. Association estimates between major gastrointestinal bleeding and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)</p> <p>Figure S6. Association between all-cause mortality and dabigatran, rivaroxaban or vitamin K antagonist (VKA) compared to apixaban for stroke prevention with atrial fibrillation or acute venous thromboembolism (VTE)</p> <p>Figure S7. Number needed to harm compared with vitamin K antagonist (VKA) considering intracranial and other major non gastrointestinal bleeding</p>
---	---

**Table S1. Definition of presumed indication of oral anticoagulant, and co-morbidities**

Conditions	ICD-10 code	"Medical act" code	ATC code
AF peripheral embolism ischemic stroke	I490x, R002x, I470x, I48x, I481x, I482x, I480x, I489x, I500x, I501x, I743x, I471x, I495x, I509x, I742x, I110x, I498x, K550x, I499x, I479x, I745x, R000x, I744x, E059x, I740x, E058x, I748x, K551x, I132x, E055x, I130x, I741x, R008x, R4700x, I63x, G45x, I670x, I64x, I652x, I651x, I653x, I658x, I694x	DEMP001, DEMP002, YYYYY490, DKRP004, DZQM002, DAQM003, DEQP001, EQRP002, GLRP004, DZQJ001, DEQP002, DZQJ008, DZQJ011, DZQJ010, DZQJ009, DEQP004, DEQP003, DZQM006, DEQP007, DZQM005, DZQJ001, DEQP005, DERP003, DZQJ008, DZQJ006, EEFA004, EEFA002, ECFA002, DERP004, DEQP001, EEFA001, EBQM002, EBQM001, ACQH003, EBQM003, ACQJ002, ACQN001, ACQJ001, ACQN004, EAQM003	
Venous thromboembolism	I26x, I801x, I802x, I803x, I808x, I809x, I81x, I822x, I823x, I829x, I636x, I676x, I828x, G08x, I800x, I820x, O871x, I821x, K751x, O223x	DHQH003, DHQM002, ECQH010, ECQH011, EFQM001, EJQH003, EJQM003, EJQM004, EJQM004, EJQP001, EMQH001, EQBP001, GFQL002, GFQL006, ZBQH001	
Lower limb orthopaedic surgery	T840x, Y831x, Z470x, Z966x	BFKA001, DBKA006, LFCA001, LHCA002, LHQH001, MBCA005, MDCA011, MDCB003, MEQH001, MGDA002, MGQH001, MHDB001 MHEP002, MHQH001, MZJB001, MZMP013, MZMP015, MZQH001, NAFA002, NBKA001, NBKA004 to NBKA006, NBKA010, NBKA014, NBKA015, NBCB003, NBCB004, NBFA003, NBMA002, NBMA003, NBPA011, NBPA016, NCCA002, NCCA004, NCCA007, NCCA012, NCCA014, NCCA017, NCCA018, NCCB006, NCEP002, NCFA006, NCPA001 to NCPA003, NCPA008, NCPA013 to NCPA0015, NDCA006, NDEP001, NDFA002, NDGA003, NDPA002 to NDPA004, NDPA011, NDPA013, NDPA014, NEEP002, NEFA004, NEFC001, NEJA001, NEKA001 to NEKA0021, NELA003, NEMA018, NEMA020, NEMA021, NFCA002, NFCA003, NFCC002, NFEA002, NFEC002, NFFA002, NFFA004, NFFC001 to NFFC004, NFJA001, NFJA002, NFJC002, NFKA001, NFKA002, NFKA004 to NFKA009, NFMA002, NFMA004, NFMC002, NFMC003, NFMP001, NFMP002, NFPA002, NFPC001, NFQC001, NFQH001 NFQP001, NFRP001, NGCA001, NGDA002, NGDA004, NGJA001, NGMP001, NGMP002, NGQH001, NHDA003 to NHDA005, NHFA001, NHMA002, NHMA008, NJCA001, NJEA002, NJEA003, NJFA005, NJMA002, NJMA004, NJPA018, NJPA025, NJPA029, NZJB001, NZMP003, NZMP006, NZMP008, NZMP014, NZQH002, PAGA009 to PAGA011, PAGB004, PAPA003, ZEMP006,	
Valvular heart disease	I05x, I080x, I081x, I083x, I342x, Z952x, Z953x, Z954x I350x, I340x, I351x, I352x, I330x, I361x, I060x,	YYYYY108, YYYYY118, DBMA011, DGKA025, DGKA011, DBKA011, DBQM001, DBKA006, YYYYY062, DBMA002, DBMA003, DZQJ002, DBLF001, DBKA011, DBKA009	

	I341x, Q231x, I062x, I348x, I371x', I339x, I38x, I398x, I088x, I089x', I349x, I358x, I391x, Q224x, Q230x		
Diabetes	E10x, E11x, E12x, E13x, E14x	BGNA001, BGNP001, BGNP004, BGNP006, BGNP007, BGNP008	A10A, A10B
Ischemic heart disease	I20 to I25	DDAF001, DDAF003 to DDAF010, DDMA003 to DDMA009, DDMA011, DDMA012, DDMA013, DDMA015 to DDMA038, DDQH006, DDQH009 to DDQH015, DDAA002, DDDFF001, DDDFF002, DDDPF002	
Hematologic or immune diseases	D50 to D89		
Lipid-lowering drug			C10AA, C10AB, C10AC01, C10AC02, C10BA02, C10BA05, C10AX, C10BX03
Antiulcer agent			A2B
Anti-platelet inhibitors			B01AC

ICD-10 stands for International Classification of Diseases, 10th revision; Medical Act classification is unique to France (CCAM nomenclature); "Medical acts" include imaging procedures such as Doppler ultrasonography (of the lower limb for a suspicion of deep vein thrombosis, echocardiography), CT scan, MRI; and therapeutic procedures (thrombectomy, fibrinolysis, thrombo-aspiration, transcutaneous cardio-version, plaster cast, osteo-synthesis, orthopaedic surgery, valve surgery, vascular by-pass, angioplasty, coronary surgery); ATC stands for Anatomical Therapeutic Chemical classification system.

**Table S2. Items included in the modified HAS-BLED score**

Letter	Original item	Modified item	New definition	ICD-10 code	Medical procedure	LTD	ATC	Score
H	Hypertension uncontrolled	Yes	Hospitalisation, LTD affiliation or treatment <sup>a</sup>	I10, I11, I15		severe arterial hypertension	C02, C03, C07-C09	1
A	Impaired renal and/or hepatic function	Yes	Hospitalisation, LTD affiliation	K70x, K713-5, K717, K721, K73, K74, Z49x, Z99x, I120, I131, N032, N033, N034, N035, N036, N037, N052, N053, N054, N055, N056, N057, N17x, N18x, N19, N250, Z490, Z492, Z940, Z992	JVJx	Liver cirrhosis, Severe chronic kidney disease		1 or 2
S	Previous history of stroke	No		G45x, I63x, I693				1
B	Previous history of bleeding	No		I312, I60-I62, I982, J942, K226, K252, K262, K270, K272, K280, K282, K290, K625, K661, K920-K922, M250, N939, R040-R043, R31, R58, S064-S066				1
L	Labile INR	Not used <sup>b</sup>						1
E	Age > 65 years (Elderly)	No						1
D	Drugs <sup>c</sup> /alcohol concomitantly	Yes	Hospitalisation related to alcohol abuse	E244x, F10x, G312x, G621x, G721x, I426x, K292x, K70x, K852x, K860x, O354x, R780x, Y90x, Z714x, Z721x, Z502x			B01AC, M01A <sup>c</sup>	1 or 2

The different criteria were assessed in the 12 months preceding inclusion date, i.e., the first observed antithrombotic delivery, except for antiplatelet agents and NSAID where the criteria were assessed between the first observed antithrombotic delivery and censure date.

Labile INR initially used in the original HAS-BLED score was not taken into account; this item does not make sense in new users or even in prevalent users of DOAC

The modified HAS-BLED score varies from 0 to 8.

Original items are those described by Pisters et al, Chest 2010; LTD stands for long-term disease registration; ATC stands for Anatomical Therapeutic Chemical Classification.

<sup>a</sup> at least two deliveries in the 12 months preceding inclusion date of a drug belonging to one of the following ATC classes: C02, C03, C07-C09;

<sup>b</sup> of note, this item is not relevant to new users of DOAC;

<sup>c</sup> antiplatelet agents (B01AC04-B01AC07, B01AC22-B01AC24, B01AC30 or B01AC56) or non-steroidal anti-inflammatory drugs (M01A, including M01AX02 (niflumic acid) and M01AX17 (nimesulide) but none of the other drugs labelled M01AX; at least one delivery concomitant with any anticoagulant.

**Table S3. Modified Charlson Score (according to Bannay et al.<sup>35</sup>)**

Factors	Weight	ICD-10 code	Medical act code	ATC code
Congestive heart failure	2	I11.0, I13.0, I13.2, I50.x		
Peripheral vascular disease	1	I70x, I71x, I731, I738, I739, I771, I790, I792, K551, K558, K559, Z958, Z95.9	DGAFx, DGCAx, DGFPx, DGKA004, EANF002, EBFAx, EBNF001, ECCA00-2, -3, -7, -9, ECFax, ECJF001, ECKA002, ECMA001, ECNF002, ECPFx, EDAF, EDCAx, EDEAx, EDFAx, EDJF, EDKAx, EDMAx, EDNFx, EDPF, EEAFAx, EECAx, EEJF001, EENF, EEPF, ENAF00-1, -2, ENFAx, ENNF,	
Cerebrovascular disease	1	G45.x, G46.x, H340, I60x-I69x		
Dementia	2	F00x–F03x, F051, G30x, G311		N06D <sup>a</sup>
CPD	1	I278, I279, J40x–J47x, J60x–J67x, J684, J701, J703		R03 <sup>b</sup>
Mild liver disease	2	B18x, K700–K703, K709, K713–K715, K717, K73x, K74x, K760, K762–K764, K768, K769, Z944		
Moderate or severe liver disease	2	I850, I859, I864, I982, K704, K711, K721, K729, K765, K766, K767		
Hemiplegia	1	G041, G114, G80-1, -2, G81x, G82x, G830–4, G839		
Moderate or severe renal disease	2	I120, I131, N032–N037, N052–N057, N18x, N19x, N250, Z490–Z492, Z940, Z992		
Any malignancy, leukemia and lymphoma	3	C00x–C26x, C30x–C34x, C37x–C41x, C43x, C45x–C58x, C60x–C76x, C81x–C85x, C88x, C90x–C97x		
Metastatic solid tumour	11	C77x–C80x		
AIDS/HIV	1	B20x–B22x, B24x, Z21		

The different criteria were assessed in the 12 months preceding inclusion date; <sup>a</sup> at least 3 deliveries; <sup>b</sup> at least 2 deliveries; CPD stands for chronic pulmonary disease; DGAF, EDAF, EEAFA, and ENAF stand for intra-luminal dilation, DGCA, EDCA stand for vascular break and/or by-pass, DGFP, DGKA004, ECKA002, ECMA001, EDKA, and EDMA stand for vascular replacement, EANF002, EBNF001, ECNF002, EDNF, EENF, and ENNF stand for fibrinolysis, EBFA, ECFA, EDFA, and ENFA stand for thromboendarterectomy, ECCA, EDEA, and EECA stand for by-pass, ECJF001, EDJF, and EEJF001 stand for thrombo-aspiration, ECPF, EDPF, and EEPF stand for recanalization.

**Table S4. Baseline characteristics in unweighted and weighted cohorts of new users of DOAC or VKA for atrial fibrillation**

	VKA N = 11 535	DOAC low-dose N = 2430	DOAC high-dose N = 10 540	Before Weighting		After Weighting	
				Standardised difference vs. VKA		Standardised difference vs. VKA	
				DOAC low-dose	DOAC high-dose	DOAC low-dose	DOAC high-dose
Age, mean year	76.5	80.6	71.6	0.098	0.112	0.005	0.005
Gender, female	49.5	56.2	42.5	0.134	0.141	0.009	0.001
Myocardial infarction	3.36	1.32	0.81	0.120	0.177	0.001	0.002
Coronary heart disease	15.6	8.19	5.87	0.213	0.316	0.007	0.006
Diabetes mellitus	18.6	14.5	14.9	0.107	0.097	0.013	0.011
Heart failure	23.1	15.9	9.28	0.174	0.379	0.013	0.006
Hypertension	58.5	56.2	46.5	0.048	0.242	0.003	0.004
Peripheral vascular disease	9.90	3.79	2.89	0.216	0.286	0.000	0.024
Cerebrovascular disease	13.4	9.22	6.76	0.125	0.219	0.020	0.019
Stroke	10.0	6.91	5.63	0.104	0.161	0.013	0.020
Dementia	4.64	3.95	1.45	0.033	0.184	0.001	0.000
Chronic pulmonary disease	18.6	16.3	13.6	0.058	0.134	0.008	0.004
Mild liver disease	1.90	0.33	0.52	0.124	0.125	0.022	0.017
Moderate or severe liver disease	0.80	0.08	0.17	0.088	0.089	0.023	0.015
Impaired hepatic function	1.24	0.21	0.29	0.101	0.108	0.027	0.016
Hemiplegia	5.08	3.25	2.13	0.086	0.157	0.010	0.020
Renal disease	10.2	3.09	1.15	0.250	0.391	0.046	0.042
Impaired renal function	12.4	3.33	1.53	0.295	0.431	0.028	0.038
Malignancy	7.09	3.79	3.66	0.134	0.152	0.021	0.016
Metastatic solid tumour	1.52	1.03	0.72	0.041	0.075	0.005	0.012
AIDS/HIV	0.10	0.00	0.01	0.035	0.038	0.025	0.010
Previous bleeding	4.65	2.35	1.41	0.114	0.188	0.006	0.007

values are percentage otherwise stated; For age, the standardized difference is  $d = \frac{(\bar{X}_1 - \bar{X}_2)}{\sqrt{\frac{s_1^2 + s_2^2}{2}}}$  For a binary categorical baseline variable, the standardized difference is  $d = \frac{(\hat{p}_1 - \hat{p}_2)}{\sqrt{\frac{(\hat{p}_1(1-\hat{p}_1) + \hat{p}_2(1-\hat{p}_2))}{2}}}$  DOAC are

dabigatran, rivaroxaban or apixaban; VKA stands for vitamin K antagonist



**Table S5. Baseline characteristics in unweighted and weighted cohorts of new users of DOAC high-dose or VKA for venous thromboembolism**

	VKA	DOAC	Standardised difference	
	N = 5 662	N = 4718	Before	After
Age, mean year	66.9	58.9	0.167	0.002
Gender, female	55.3	46.9	0.168	0.001
Myocardial infarction	0.62	0.21	0.062	0.002
Coronary heart disease	4.91	1.72	0.175	0.017
Diabetes mellitus	10.7	5.9	0.173	0.002
Hypertension	34.3	19.7	0.331	0.008
Heart failure	6.69	2.23	0.213	0.009
Peripheral vascular disease	4.50	1.61	0.165	0.001
Cerebrovascular disease	4.20	1.29	0.175	0.018
Stroke	2.33	0.66	0.135	0.007
Dementia	4.61	1.44	0.182	0.002
Chronic pulmonary disease	14.5	11.0	0.106	0.020
Mild liver disease	2.49	0.66	0.144	0.028
Moderate or severe liver disease	1.25	0.17	0.125	0.032
Impaired hepatic function	1.71	0.28	0.140	0.035
Hemiplegia	2.17	0.83	0.108	0.007
Renal disease	5.56	0.89	0.258	0.031
Impaired renal function	7.44	1.42	0.287	0.018
Malignancy	9.03	3.86	0.208	0.005
Metastatic solid tumour	2.61	0.76	0.141	0.004
AIDS/HIV	0.23	0.04	0.050	0.015
Previous bleeding	4.27	1.84	0.139	0.001

Values are percentage otherwise stated

For age, the standardized difference is  $d = \frac{(\bar{X}_1 - \bar{X}_2)}{\sqrt{\frac{s_1^2 + s_2^2}{2}}}$

For a binary categorical baseline variable, the standardized difference is  $d = \frac{(\hat{p}_1 - \hat{p}_2)}{\sqrt{\frac{[\hat{p}_1(1-\hat{p}_1) + \hat{p}_2(1-\hat{p}_2)]}{2}}}$

DOAC are dabigatran, rivaroxaban or apixaban; VKA stands for vitamin K antagonists.

**Table S6. Timing of censoring according to reason and anticoagulant**

	Vitamin K Antagonists				Apixaban High-dose				Dabigatran High-dose				Rivaroxaban High-dose			
	N	q1	q2	q3	N	q1	q2	q3	N	q1	q2	q3	N	q1	q2	q3
Dose change					209	28	60	129	305	42	165	369	472	44	130	311
Discontinuation	6619	110	162	247	187	60	91	150	339	60	91	207	4996	60	108	182
Death	1700	60	154	359	13	37	81	141	14	106	370	616	283	45	135	351
End of follow-up	10183	184	420	705	1552	77	187	316	476	510	750	925	7327	115	322	660
Major bleeding	400	46	162	359	13	137	224	251	7	20	112	552	116	55	154	389
Moving outside	338	66	176	377	14	56	106	161	20	130	387	607	127	86	222	418
Switch	965	33	86	248	57	30	57	143	120	28	92	238	1012	19	59	181

	Apixaban Low-dose				Dabigatran Low-dose				Rivaroxaban Low-dose			
	N	q1	q2	q3	N	q1	q2	q3	N	q1	q2	q3
Dose change	115	17	29	60	115	17	69	327	216	14	41	180
Discontinuation	292	60	60	82	1464	60	60	60	4257	60	60	60
Death	43	21	70	149	114	54	236	478	29	33	58	225
End of follow-up	901	60	137	267	925	338	694	917	707	49	60	89
Major bleeding	6	136	161	446	28	22	125	603	3	1	1	24
Moving outside	6	64	143	307	24	68	217	405	6	29	35	378
Switch	52	21	52	106	274	43	144	292	28	11	39	169

q1 and q3 stand for 1st and 3rd quartile, respectively; q2 stands for median.

**Table S7 Panel A. Total number of major bleeding events according to indication**

Bleeding site	AF	VTE	Orthopaedic	Unknown	All
Intracranial haemorrhage (ICH)	126	20	2	-	148
Extra/subdural	47	6	2	-	55
Intracerebral	64	12	-	-	76
Other, intraventricular or unspecified	15	2	-	-	17
Gastrointestinal (GI) bleeding	169	28	4	1	202
Upper GI	29	9			38
Lower GI	140	19	4	1	164
Other major bleeding	177	44	2	-	223
Hematuria / genitourinary	49	8	-	-	57
Oropharynx	37	9	-	-	46
Muscle (include soft tissue)	54	16	2	-	72
Other	37	11	-	-	48
All	472	92	8	1	573

AF denotes atrial fibrillation, VTE acute venous thromboembolism

**Table S7 Panel B. Total number of major bleeding events according to anticoagulant**


Bleeding site	VKA	Dabigatran		Rivaroxaban		Apixaban		All
		High	Low	High	Low	High	Low	
Intracranial haemorrhage (ICH)	105	0	6	31	1	4	1	148
Extra/subdural	41		3	9	0	1	1	55
Intracerebral	54		2	18	1	1	0	76
Other, intraventricular or unspecified	10		1	4	0	2	0	17
Gastrointestinal (GI) bleeding	126	5	16	46	1	6	2	202
Upper GI	27	1	0	7	0	2	1	38
Lower GI	99	4	16	39	1	4	1	164
Other major bleeding	169	2	6	39	1	3	3	223
Hematuria / genitourinary	41	1	2	10	0	1	2	57
Oropharynx	30	1	0	14	1	0	0	46
Muscle (include soft tissue)	65	0	1	5	0	1	0	72
Other	33	0	3	10	0	1	1	48
All	400	7	28	116	3	13	6	573

Accel


**Table S8. Crude incidence rates of bleeding events by anticoagulant exposure, dose and HAS-B(L)ED score level**

			Vitamin K antagonist			DOAC		
			No of events	Person years	Incidence rate per 100 py (95% CI)	No of events	Person years	Incidence rate per 100 py (95% CI)
HAS-B(L)ED 0-1	Low dose	Intracranial haemorrhage				3	1760	0.17 (0.05 - 0.53)
		Gastrointestinal bleeding				11	1760	0.62 (0.35 - 1.13)
		Other major bleeding				4	1760	0.23 (0.09 - 0.61)
	High dose	Intracranial haemorrhage	26	6775	0.38 (0.26 - 0.56)	20	7068	0.28 (0.18 - 0.44)
		Gastrointestinal bleeding	31	6775	0.46 (0.32 - 0.65)	16	7068	0.23 (0.14 - 0.37)
		Other major bleeding	48	6775	0.71 (0.53 - 0.94)	15	7068	0.21 (0.13 - 0.35)
HAS-B(L)ED 2	Low dose	Intracranial haemorrhage				5	1731	0.29 (0.12 - 0.69)
		Gastrointestinal bleeding				3	1731	0.17 (0.06 - 0.54)
		Other major bleeding				7	1731	0.40 (0.19 - 0.85)
	High dose	Intracranial haemorrhage	42	6627	0.63 (0.47 - 0.86)	8	4792	0.17 (0.08 - 0.33)
		Gastrointestinal bleeding	33	6627	0.50 (0.35 - 0.70)	27	4792	0.56 (0.39 - 0.82)
		Other major bleeding	71	6627	1.07 (0.85 - 1.35)	33	4792	0.69 (0.49 - 0.97)
HAS-B(L)ED >2	Low dose	Intracranial haemorrhage				0	852	0.00 (0.00 - 0.43)
		Gastrointestinal bleeding				5	852	0.59 (0.24 - 1.41)
		Other major bleeding				2	852	0.23 (0.06 - 0.94)
	High dose	Intracranial haemorrhage	37	5386	0.69 (0.50 - 0.95)	7	1922	0.36 (0.17 - 0.76)
		Gastrointestinal bleeding	62	5386	1.15 (0.90 - 1.48)	14	1922	0.73 (0.43 - 1.23)
		Other major bleeding	67	5386	1.24 (0.98 - 1.58)	7	1922	0.36 (0.17 - 0.76)

**Figure S1. Figure Reason of censoring (expressed as percentage) across drug classes.**




**Figure S2. Crude incidence rates of bleeding according to HAS-(B)LED strata and time period**




ICH denotes intracranial bleeding, and GI gastrointestinal; DOAC stands for direct oral anticoagulant; high-dose (dabigatran 300 mg or rivaroxaban 15 or 20 mg or apixaban 10 mg per day), low-dose (dabigatran 220 mg or rivaroxaban 10 mg or apixaban 5 mg per day)

**Figure S3. Association estimates between different location of other major bleeding event, and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)**




**Figure S4. Association estimates between each major bleeding event, all-cause mortality, and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)**



Accepted




**Figure S5. Association estimates between major gastrointestinal bleeding and direct oral anticoagulant (DOAC) compared to vitamin K antagonist (VKA)**




Accepte

**Figure S6. Association between all-cause mortality and dabigatran, rivaroxaban or vitamin K antagonist (VKA) compared to apixaban for stroke prevention with atrial fibrillation or acute venous thromboembolism (VTE)**



**Figure S7. Number needed to harm compared with vitamin K antagonist (VKA) considering intracranial and other major non gastrointestinal bleeding**



The calculations are based on the hazard ratios from adjusted Cox proportional hazard models with a given set of covariates (notably HASBLED score = 2, and modified Charlson score = "1-2").

Accce